Mind Medicine (mindmed) INC

Definium Therapeutics announced positive topline results from its Phase 3 Voyage study of DT120 ODT for generalized anxiety disorder, meeting primary and key secondary endpoints.

Definium Therapeutics announced positive Phase 3 Emerge study results for DT120 ODT in MDD, substantial cash reserves, and progress across its GAD and MDD clinical programs.

Definium Therapeutics has priced an underwritten public offering of common shares, raising approximately $805 million in gross proceeds.

Definium Therapeutics, Inc. has released an updated corporate presentation on May 19, 2026, detailing its late-stage pipeline for DT120 ODT in GAD and MDD, and DT402 for ASD, alongside its financial position and future milestones.

Definium Therapeutics has dosed the first patient in its Phase 3 Ascend study for DT120 ODT in Major Depressive Disorder, with topline data expected in 2027.

Definium Therapeutics announced significant clinical progress for its DT120 ODT program with three pivotal readouts expected in 2026.

Definium Therapeutics reported increased operating expenses and a wider net loss in Q1 2026, driven by significant investment in its DT120 and DT402 clinical programs, while advancing key trials.

Mind Medicine (MindMed) Inc. reported a significant increase in net loss and R&D expenses for Q3 2025, but bolstered its financial position with a $242.8 million capital raise post-quarter, extending its cash runway into 2028.

Mind Medicine (MindMed) Inc. reported increased net losses and cash burn in Q2 2025 as it significantly ramps up Phase 3 clinical trials for its lead product candidates, MM120 and MM402, while securing new debt financing.

MindMed's Q1 2025 results show increased R&D spending and a net loss, but the company is progressing with its clinical trials and has secured additional financing.

MindMed's Q3 2024 report highlights progress in clinical trials for MM120 and MM402, along with a strong cash position following recent financings.

MindMed's second quarter 2024 results show a net loss of $5.9 million, but the company has secured significant funding and is advancing its clinical programs.

Definium Therapeutics reports increased net losses for 2025 while progressing its lead psychedelic-based drug candidates, DT120 and DT402, into pivotal clinical trials for anxiety, depression, and autism spectrum disorder.

MindMed's 2024 10-K filing highlights advancements in clinical trials for brain health disorders, including positive results for MM120 in GAD and initiation of Phase 3 trials.

Mind Medicine (MindMed) Inc. details its share capital, voting rights, dividend policy, and regulatory compliance in its latest 10-K filing.

Robert Barrow, Chief Executive Officer and a Director of Mind Medicine (MindMed) Inc., received 375,000 shares of common stock on August 12, 2026.

Daniel Karlin, Chief Medical Officer of Mind Medicine (MindMed) Inc., received 100,000 shares of common stock on August 12, 2026.

Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., received 62,500 shares of common stock on August 12, 2026.

Matthew T. Wiley, Chief Commercial Officer of Mind Medicine (MindMed) Inc., received 62,500 shares of common stock on August 12, 2026.

Brandi Roberts, Chief Financial Officer of Mind Medicine (MindMed) Inc., received 62,500 shares of common stock on August 12, 2026.

Definium Therapeutics Chief Legal Officer Mark Sullivan sold 13,008 common shares to cover tax withholding obligations under a Rule 10b5-1 plan.

Definium Therapeutics, Inc. announced its Annual General and Special Meeting of Shareholders will be held virtually on June 11, 2026, to elect directors, appoint auditors, and approve an equity incentive plan amendment.

MindMed will hold its Annual General and Special Meeting virtually on June 12, 2025, with shareholders able to vote on key proposals including the election of directors, appointment of auditors, and approval of the 2025 Equity Incentive Plan.

MindMed announces its Annual General and Special Meeting of Shareholders to be held virtually on June 12, 2025, featuring proposals for director elections, auditor appointment, and approval of a new equity incentive plan.

Mind Medicine (MindMed) Inc. announces its 2024 Annual General and Special Meeting to be held virtually on June 10, 2024, outlining proposals for shareholder voting including the election of directors, appointment of an auditor, and approval of an employee share purchase plan.

MindMed's upcoming annual meeting on June 10, 2024, will address the election of directors, appointment of an auditor, and approval of an employee share purchase plan.

Commodore Capital LP and its affiliates have reported a beneficial ownership of 1.8% of Definium Therapeutics, Inc. common shares, acquiring them through a combination of direct holdings and pre-funded warrants.

Driehaus Capital Management LLC has amended its Schedule 13G filing to report a decrease in its beneficial ownership of Definium Therapeutics, Inc. common stock to 5.36% as of June 30, 2026.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly reported beneficial ownership of 3,000,000 shares, representing 3.01% of Definium Therapeutics, Inc. common stock as of March 31, 2026.

Driehaus Capital Management LLC reports a 6.64% beneficial ownership stake in Definium Therapeutics, Inc., holding over 6.5 million shares.

Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have disclosed a 5.08% beneficial ownership stake in Mind Medicine (MindMed) Inc. for investment purposes.

Deep Track Capital, LP and affiliates reported a 5.54% beneficial ownership stake in Definium Therapeutics, Inc. as of December 31, 2025.